Patients who are prescribed an atypical antipsychotic, such as olanzapine (Zyprexa), should be monitored for:

Monoamine oxidase inhibitors (MAOIs) are a class of antidepressants used primarily in treatment-resistant depression and some anxiety disorders. They work by increasing levels of key monoamine neurotransmitters in the brain, including serotonin, norepinephrine, and dopamine. This is achieved through inhibition of the enzyme responsible for breaking down these neurotransmitters. Understanding this mechanism is essential because it also explains their significant food and drug interaction risks.

Rationale:
A. Monoamine oxidase inhibitors do not work by inhibiting dopamine production in the hypothalamus or limbic system. Instead, they act after neurotransmitters are released, affecting their breakdown rather than their synthesis. Dopamine production itself is not directly suppressed by this medication class.

B. Inhibition of 5-HT2 receptors on the postsynaptic membrane is the mechanism of atypical antipsychotics, not MAOIs. Monoamine oxidase inhibitors do not exert their primary effect through receptor blockade but through preventing enzymatic degradation of monoamines. This option describes a different pharmacologic class entirely.

C. Inhibition of serotonin (5-HT) and norepinephrine reuptake into the presynaptic neuron is the mechanism of action of selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs). MAOIs do not block reuptake transporters; instead, they prevent breakdown of neurotransmitters within the neuron and synaptic cleft.

D. Monoamine oxidase inhibitors work by inhibiting the monoamine oxidase enzyme responsible for breaking down dopamine, norepinephrine, and serotonin in the brain. This leads to increased availability and prolonged action of these neurotransmitters in the synaptic cleft. This mechanism explains both their antidepressant effects and their high risk for serious drug and food interactions.

Diaper dermatitis is an inflammatory skin condition in infants caused by prolonged exposure to moisture, friction, urine, and feces, often complicated by irritant or mild inflammatory processes. Treatment focuses on reducing inflammation, protecting the skin barrier, and minimizing exposure to irritants. Topical corticosteroids may be used cautiously when inflammation is present, but potency and safety are critical considerations due to the increased absorption in diaper-covered skin.

Rationale:
A. High-potency corticosteroids such as Betamethasone dipropionate 0.05% are not appropriate for diaper dermatitis because infant skin, especially in the diaper area, has increased absorption leading to a higher risk of systemic steroid effects such as hypothalamic-pituitary-adrenal (HPA) axis suppression and skin atrophy. These agents are reserved for severe inflammatory dermatologic conditions, not routine diaper rash.

B. Low-potency corticosteroids such as Hydrocortisone 1% are the safest option when a corticosteroid is needed for diaper dermatitis. They effectively reduce mild inflammation while minimizing the risk of systemic absorption and local adverse effects. Short-term use is recommended, along with barrier protection and frequent diaper changes.

C. Corticosteroids are not absolutely contraindicated in diaper dermatitis; low-potency agents may be used briefly when significant inflammation is present. Avoiding them entirely is not necessary in all cases. However, they should be used cautiously and not as first-line monotherapy without barrier care.

D. Intermediate potency corticosteroids such as Triamcinolone 0.1% are too strong for routine use in diaper dermatitis. The occlusive nature of the diaper area increases absorption, raising the risk of systemic side effects and skin damage. These agents are generally reserved for more severe inflammatory skin disorders in less sensitive areas.